# A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

> **NCT05953740** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 17 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** MK-5720
- **DRUG:** Placebo to MK-5720
- **DRUG:** MK-8189
- **DRUG:** Placebo to MK-8189

## Key facts

- **NCT ID:** NCT05953740
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-15
- **Primary completion:** 2024-02-15
- **Final completion:** 2024-02-15
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05953740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05953740, "A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05953740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*